IntuitionLabs is now a member of the Claude Partner Network – AI training and upskilling with Claude for pharma and biotech. Book a call.
Compares Microsoft 365 Copilot, Google Gemini Enterprise, ChatGPT Enterprise, Claude Enterprise, and AWS Bedrock plus Veeva Vault AI for pharma GxP validation, pricing, and 21 CFR Part 11 readiness as of 2026.
A 2026 analyst guide to the ICH M15 model-informed drug development guideline: the six-element risk framework, FDA and EMA timelines, MAP/MAR requirements, and five real case studies.
An educational guide to the FDA ISTAND program, explaining the DDT qualification process and the regulatory integration of AI-based drug development tools.
How pharma companies meet EU AI Act Article 4 AI literacy rules in 2026: requirements, deadlines, penalties, GxP integration, and named training programs at J&J, Merck, and Samsung Bioepis.
A 2026 analyst comparison of biotech AI enablement programs versus one-time AI workshops, covering pricing bands from $2,500 to $250,000, named cases at J&J, AstraZeneca, Sanofi, and Moderna, and FDA/EU AI Act compliance implications.
A 2026 guide to building an AI roadmap for biotech: data readiness, use-case sequencing, FDA/EMA and EU AI Act governance, talent, and 5 named case studies including Roche, Novo Nordisk, and Insilico Medicine.
A 2026 analyst guide to evaluating AI consulting for life sciences: market sizing, FDA/EMA/EU AI Act rules, vendor scorecards, pricing benchmarks, and five named case studies.
A 2026 analyst guide to AI governance in biotech: council charter templates, decision rights (RACI), FDA/EMA principles, EU AI Act deadlines, and six company case studies.
Compares AI enablement models for biotech in 2026: Big Four consultancies, McKinsey QuantumBlack, IQVIA, boutique firms, training providers, and building an internal AI team, with pricing, adoption data, and 6 case studies.
A 2026 pricing guide covering biotech AI implementation cost across pilot, single use-case, and enterprise tiers, consulting fee benchmarks, GPU infrastructure pricing, and case studies from Recursion, Insilico Medicine, and Novo Nordisk.
A 2026 phased breakdown of the biotech AI strategy timeline, covering 90-day diagnostics, board approval, team building, and 2-3 year scaling, with GSK, Merck, and Moderna case data.
A 2026 guide to AI enablement for biotech covering a 12-week implementation roadmap, workshop pricing from $3,500 to $5,500, a $2.9 billion drug discovery AI market, and FDA and EU AI Act compliance requirements.
A 2026 methodology guide to running an AI opportunity assessment in biotech: readiness diagnostics, a five-axis use case prioritization matrix, FDA and EU AI Act context, and five named case studies.
A 2026 analyst guide to AI for biotech intellectual property: patent search tools, drafting platforms, USPTO/EPO inventorship rules, pricing, and case studies.
A 2026 analyst guide to building an AI Center of Excellence in biotech: hub-spoke-hybrid models, FDA/EMA/NIST governance, staffing budgets from $2M to $200M, and named cases from Sanofi, Merck, Novartis, AstraZeneca, and GSK.
A 2026 framework for prioritizing biotech AI use cases by impact, data readiness, and regulatory risk, with verified adoption, ROI, and FDA governance data.
A 2026 data-driven benchmark of AI enablement in biotech covering adoption surveys, drug discovery market sizing, FDA/EMA guidance, and five real-world case studies including Insilico Medicine and Isomorphic Labs.
A 2026 analyst guide to measuring AI adoption versus AI impact, covering adoption metrics, training effectiveness, ROI frameworks, KPI trees, and named enterprise case studies like Novo Nordisk and Sanofi.
Data-driven benchmarks on 2026 biotech AI budgets covering percent of R&D spend, mid-cap CoE costs (about $2M), implementation timelines, GPU pricing, and ROI evidence.
A 2026 framework for biotech AI strategy: a five-axis prioritization matrix, FDA/EMA risk tiering, data readiness benchmarks, ROI data, and five named case studies including Insilico, Recursion, and Xaira.
A 2026 analyst framework mapping biotech and pharma AI adoption across five maturity stages, from shadow AI use to autonomous agentic systems, with governance, GxP validation, and regulatory benchmarks.
Analyst report on AI in preclinical development in 2026: market size, FDA credibility framework and animal-testing roadmap, organ-on-chip adoption, and five named case studies.
A 2026 analysis of how AI transforms biotech finance operations, covering close automation, CRO accrual management, ERP integration, governance, and named CFO case studies from Biogen, IQVIA, and Lineage Cell Therapeutics.
Learn how pharmaceutical companies license proprietary R&D data to train AI foundation models. Analyze deal structures, pricing terms, and key case studies.
© 2026 IntuitionLabs. All rights reserved.
